An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.

Bhattacharyya, M

An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. [electronic resource] - Cancer gene therapy Oct 2011 - 734-43 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1476-5500

10.1038/cgt.2011.45 doi


Adenocarcinoma--drug therapy
Adenoviruses, Human--genetics
Animals
Antineoplastic Agents--therapeutic use
Cell Line, Tumor
Cell Survival
Combined Modality Therapy
Cytopathogenic Effect, Viral
Deoxycytidine--analogs & derivatives
Fluorouracil--therapeutic use
Gene Deletion
Gene Expression Regulation, Viral--drug effects
Humans
Kaplan-Meier Estimate
Mice
Mice, Inbred C57BL
Mice, Nude
Oncolytic Virotherapy
Oncolytic Viruses--genetics
Pancreatic Neoplasms--drug therapy
Receptors, Virus--metabolism
Retinoblastoma Protein--metabolism
Virus Replication--genetics
Xenograft Model Antitumor Assays
Gemcitabine